Critical Path Institute Resources

C-Path Awarded FDA Drug Development Tool Research Grant to Develop a Qualification Plan for the PROMIS® Short Form v2.1—Physical Function-Multiple Sclerosis 15a (PROMIS PFMS—15a)

C-Path’s Patient-Reported Outcome (PRO) Consortium announced today it has been awarded a U.S. Food and Drug Administratio

C-Path’s Patient-Reported Outcome (PRO) Consortium announced that it has been awarded a U.S. Food and Drug Administration (FDA)

Launched by C-Path and NORD through an FDA grant, the goal of the new platform is to accelerate the development of cures by addres

The presentations of the workshop sessions are now available. In order to download the presentations...

C-Path and its Critical Path for Parkinson’s Consortium are pleased to share a new manuscript that redefines Parkinson’s...

Conrado, D.J., et al.; “FDA qualification of intracranial adjusted hippocampal volumetric magnetic resonance imaging (ICV-HV vMR

Critical Path for Alzheimer’s Disease (CPAD) consortium’s refined, refocused mission centers on accelerating therapy developme

At its 10th Annual Meeting and Regulatory Science Workshop, November 13, 2018, in Bethesda, MD, C-Path’s Critical Path for Alzhe

Effective treatments for both existing and emerging diseases may already be available on pharmacy shelves. Many approved drugs...